PAR · ALTHX.PA
THX Pharma
€3.48+€0.02 (+0.58%)
THX Pharma’s quoted price sits in the upper half of its reported 52-week range, 31.76% below the high.
Loading market information…
PAR · POXEL.PA · EUR
Stock price, earnings
Quote as of Oct 29, 2026, 04:35 PM UTC. Cached market data; not a live quote.
One-year closing-price history · EUR. Historical prices are not a forecast.
Poxel S.A.’s quoted price sits in the lower half of its reported 52-week range, 64.29% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Poxel S.A.’s next earnings report is currently expected on Mar 24, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Poxel S.A.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Poxel S.A. is a clinical-stage biopharmaceutical firm dedicated to discovering innovative therapies for a range of conditions, including metabolic disorders, type 2 diabetes, and liver ailments. Its most advanced investigational drug, Imeglimin, is an oral medication candidate for type 2 diabetes. This treatment has successfully completed Phase III trials in Japan and is currently undergoing Phase III development in both the United States and Europe. Imeglimin works by enhancing pancreatic beta cell function, reducing insulin resistance, and mitigating significant cardiovascular and metabolic risk factors like elevated blood lipid levels and excessive body weight. Beyond Imeglimin, Poxel is also advancing PXL770, an activator of the adenosine monophosphate-activated protein kinase (AMPK) enzyme. This compound is presently in a Phase 2a clinical trial, targeting various chronic metabolic diseases, notably those affecting the liver, such as non-alcoholic steatohepatitis (NASH). Furthermore, the company has strategic collaborations for other pipeline assets. Under a licensing agreement with Enyo Pharma S.A.S., Poxel is developing PXL007 (also known as EYP001), a synthetic non-steroidal and non-bile acid FXR agonist, which is currently in a Phase II study for treating hepatitis B and NASH. Another partnership with DeuteRx LLC focuses on PXL065, a mitochondrial pyruvate carrier inhibitor, now in a Phase I clinical trial specifically for NASH. Established in 2009, Poxel S.A. operates from its headquarters in Lyon, France.
Latest available per-share figures in EUR. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:27 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| -€0.46+24.59% vs estimate |
| €83.00K0.0% vs estimate |
| Q4 2021 | May 17, 2022 | -€0.55 | €123.00K |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
€3.48+€0.02 (+0.58%)
THX Pharma’s quoted price sits in the upper half of its reported 52-week range, 31.76% below the high.
€0.31€0.00 (0.0%)
Nicox S.A.’s quoted price sits in the lower half of its reported 52-week range, 45.52% below the high.
€2.07-€0.03 (-1.43%)
genOway S.A.’s quoted price sits in the lower half of its reported 52-week range, 28.13% below the high.
€0.65+€0.02 (+3.67%)
Valbiotis S.A.’s quoted price sits in the lower half of its reported 52-week range, 50.08% below the high.
€1.43+€0.03 (+2.14%)
Ikonisys S.A.’s quoted price sits in the lower half of its reported 52-week range, 22.28% below the high.
€0.14+€0.02 (+16.5%)
TME Pharma N.V.’s quoted price sits in the upper half of its reported 52-week range, 19.93% below the high.
€0.07-€0.00 (-1.07%)
GenSight Biologics S.A.’s quoted price sits in the lower half of its reported 52-week range, 68.91% below the high.
€0.74+€0.07 (+10.45%)
Aelis Farma S.A.’s quoted price sits in the lower half of its reported 52-week range, 67.83% below the high.
